Israel - English - Ministry of Health

organon pharma israel ltd., israel - follitropin beta - solution for injection - follitropin beta 833 iu / 1 ml - follitropin beta - follitropin beta - puregon is indicated for the treatment of female infertility in the following clinical situations: anovulation (including polycystic ovarian disease, pcod) in women who have beenunresponsive to treatment with clomiphene citrate. controlled ovarian hyperstimulation to induce the development of multiple follicles in medically assisted reproduction programs [ e.g. in vitro fertilisation/embryo transfer (ivf/et), gamete intra-fallopian transfer (gift) and intracytoplasmic sperm injection (icsi)]. in the male : deficient spermatogenesis due to hypogonadotrophic hypogonadism.

Israel - English - Ministry of Health

merck serono ltd - choriogonadotropin alfa - solution for injection - choriogonadotropin alfa 250 mcg / 0.5 ml - choriogonadotropin alfa - choriogonadotropin alfa - - for women undergoing superovulation prior to assisted reproductive techniques such as in vitro fertilization (ivf) : ovitrelle is administered to trigger final follicular maturation and luteinisation after stimulation of follicular growth. - anovulatory or oligo-ovulatory women: ovitrelle is administered to trigger ovulation and luteinisation in anovulatory or oligo-ovulatory patients after stimulation of follicular growth.

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - follitropin beta, quantity: 833 iu/ml - injection, solution - excipient ingredients: sucrose; sodium citrate dihydrate; polysorbate 20; benzyl alcohol; methionine; hydrochloric acid; sodium hydroxide; water for injections - female: anovulatory infertility and; controlled ovarian hyperstimulation to induce the development of multiple follicles in medically assisted reproduction programs (e.g. in vitro fertilisation and related procedures). male: for the treatment of deficient spermatogenesis due to hypogonadotrophic hypogonadism.

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - follitropin beta, quantity: 833 iu/ml - injection, solution - excipient ingredients: sucrose; sodium citrate dihydrate; polysorbate 20; benzyl alcohol; methionine; hydrochloric acid; sodium hydroxide; water for injections - in the female: anovulatory infertility and; controlled ovarian hyperstimulation to induce the development of multiple follicles in medically assisted reproduction programs (e.g. in vitro fertilisation and related procedures). in the male: for the treatment of deficient spermatogenesis due to hypogonadotrophic hypogonadism.

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - follitropin beta, quantity: 833 iu/ml - injection, solution - excipient ingredients: sucrose; sodium citrate dihydrate; polysorbate 20; benzyl alcohol; methionine; hydrochloric acid; sodium hydroxide; water for injections - in the female: anovulatory infertility and; controlled ovarian hyperstimulation to induce the development of multiple follicles in medically assisted reproduction programs (e.g. in vitro fertilisation and related procedures). in the male: for the treatment of deficient spermatogenesis due to hypogonadotrophic hypogonadism.

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - follitropin beta, quantity: 833 iu/ml - injection, solution - excipient ingredients: sucrose; sodium citrate dihydrate; polysorbate 20; benzyl alcohol; methionine; hydrochloric acid; sodium hydroxide; water for injections - female: anovulatory infertility and; controlled ovarian hyperstimulation to induce the development of multiple follicles in medically assisted reproduction programs (e.g. in vitro fertilisation and related procedures). male: for the treatment of deficient spermatogenesis due to hypogonadotrophic hypogonadism.

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - follitropin beta, quantity: 833 iu/ml - injection, solution - excipient ingredients: sucrose; sodium citrate dihydrate; polysorbate 20; benzyl alcohol; methionine; hydrochloric acid; sodium hydroxide; water for injections - in the female: anovulatory infertility and; controlled ovarian hyperstimulation to induce the development of multiple follicles in medically assisted reproduction programs (e.g. in vitro fertilisation and related procedures). in the male: for the treatment of deficient spermatogenesis due to hypogonadotrophic hypogonadism.

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - follitropin beta, quantity: 833 iu/ml - injection, solution - excipient ingredients: sucrose; sodium citrate dihydrate; polysorbate 20; benzyl alcohol; methionine; hydrochloric acid; sodium hydroxide; water for injections - in the female: anovulatory infertility and; controlled ovarian hyperstimulation to induce the development of multiple follicles in medically assisted reproduction programs (e.g. in vitro fertilisation and related procedures). in the male: for the treatment of deficient spermatogenesis due to hypogonadotrophic hypogonadism.

Australia - English - Department of Health (Therapeutic Goods Administration)

merck healthcare pty ltd - choriogonadotropin alfa, quantity: 250 microgram - injection, solution - excipient ingredients: mannitol; water for injections; methionine; dibasic sodium phosphate dihydrate; poloxamer; phosphoric acid; sodium hydroxide; monobasic sodium phosphate monohydrate - ovidrel is indicated in the treatment of (i) women undergoing superovulation prior to assisted reproductive techniques such as in vitro fertilisation (ivf): ovidrel is administered to trigger final follicular maturation and luteinisation after stimulation of follicular growth. (ii) anovulatory or oligo-ovulatory women: ovidrel is administered to trigger ovulation and luteinisation in anovulatory or oligo-ovulatory patients after stimulation of follicular growth.

Australia - English - Department of Health (Therapeutic Goods Administration)

ferring pharmaceuticals pty ltd - human menopausal gonadotrophin, quantity: 1200 iu - injection, solvent for - excipient ingredients: water for injections; metacresol - menopur is indicated for the treatment of infertility in the following clinical situations:,anovulatory infertility, including polycystic ovarian disease (pcod), in women who have been unresponsive to treatment with clomiphene citrate.,controlled ovarian hyperstimulation to induce the development of multiple follicles for assisted reproductive technologies (art) (e.g. in vitro fertilisation/embryo transfer (ivf/et), gamete intra-fallopian transfer (gift) and intracytoplasmic sperm injection (icsi)).